As the Chief Investment Officer and Managing Partner at AIF, Robert Sarrazin plays a pivotal role in driving the fund's mission to transform the landscape of autism diagnosis and treatment. With a robust background in private equity and corporate development, Robert leverages his extensive expertise...
As the Chief Investment Officer and Managing Partner at AIF, Robert Sarrazin plays a pivotal role in driving the fund's mission to transform the landscape of autism diagnosis and treatment. With a robust background in private equity and corporate development, Robert leverages his extensive expertise in sourcing, evaluating, and managing a diverse portfolio of control investments. His experience spans strategic transactions for a Fortune 500 healthcare company and over 30 middle-market growth acquisitions across various private equity funds, positioning him as a leader in the field.
At AIF, Robert is at the forefront of innovative projects that aim to harness emerging technologies and translational science to improve the lives of individuals with autism. His strategic vision is instrumental in identifying and nurturing groundbreaking ventures that align with AIF’s commitment to early diagnosis and effective treatment solutions. By utilizing a venture capital model, he ensures that innovative services are not only developed but also brought to market efficiently, thereby accelerating their impact on patient care.
Robert's deep understanding of the pharmaceutical industry, combined with his skills in corporate finance and business strategy, enables him to navigate the complexities of alternative investments and growth capital. His proficiency in innovation management and leveraged lending further enhances AIF's ability to support transformative initiatives in the autism space. Through his leadership, Robert Sarrazin is not just investing in companies; he is championing a future where autism is understood and treated with the urgency and compassion it deserves.
